How should I transition from escitalopram (Lexapro) 10 mg to bupropion (Wellbutrin) 150 mg?

How to Switch from Lexapro 10mg to Wellbutrin 150mg

The safest approach is to taper escitalopram to 5mg for 3-7 days while simultaneously starting bupropion 150mg once daily in the morning, then discontinue escitalopram completely after this brief overlap period. This cross-taper minimizes both discontinuation syndrome from the SSRI and allows monitoring for early bupropion tolerability 1, 2.

Recommended Switching Protocol

Week 1: Initiation Phase

• Day 1-3: Start bupropion 150mg once daily in the morning while continuing escitalopram 10mg 2
• Day 4-7: Reduce escitalopram to 5mg daily while continuing bupropion 150mg 1
• Day 8 onward: Discontinue escitalopram completely, continue bupropion 150mg alone 2

This approach provides a brief overlap period that reduces the risk of discontinuation syndrome, which is characterized by dizziness, fatigue, nausea, sensory disturbances, anxiety, and irritability that can occur with abrupt SSRI cessation 1. Escitalopram has a relatively short half-life compared to fluoxetine, making a brief taper prudent 1.

Dose Titration of Bupropion

• After 4 days at 150mg once daily, the dose may be increased to 300mg once daily if clinically indicated and well-tolerated 2
• If increasing to 300mg, continue as a single morning dose rather than splitting 2
• Critical timing: Administer bupropion before 3 PM to minimize insomnia risk 3

Early Monitoring Requirements (First 1-2 Weeks)

Intensive monitoring during the first 1-2 weeks is mandatory to identify early adverse effects and ensure safe transition 3. Specifically assess for:

• Neuropsychiatric symptoms: Suicidal ideation, agitation, irritability, akathisia, worsening anxiety, panic symptoms, unusual behavioral changes, hostility, and impulsivity 1, 3
• Discontinuation syndrome from escitalopram: Dizziness, vertigo, paresthesias, sensory disturbances, headache, nausea, insomnia, anxiety 1
• Activation symptoms from bupropion: Insomnia, tremor, agitation (the highest risk period for neuropsychiatric events is the first 1-2 months) 3

Contraindications and Safety Screening

Before initiating bupropion, absolutely rule out the following contraindications 3, 2:

• History of seizure disorder or conditions lowering seizure threshold (stroke, brain metastases, eating disorders—anorexia or bulimia)
• Current or recent (within 14 days) MAOI use
• Abrupt discontinuation of alcohol or benzodiazepines
• Closed-angle glaucoma
• Concurrent tamoxifen therapy (bupropion inhibits CYP2D6, reducing tamoxifen efficacy)

Rationale for This Switching Strategy

Why Cross-Taper Rather Than Direct Switch?

• Escitalopram has relatively low drug interaction potential via CYP450 enzymes compared to other SSRIs, making brief overlap safer 1
• No serotonin syndrome risk: Bupropion has no serotonergic activity, eliminating concerns about combining it with escitalopram during the taper 4
• Prevents treatment gap: Maintains antidepressant coverage during the transition, reducing relapse risk 5

Evidence Supporting Bupropion as Alternative

• Bupropion demonstrates non-inferior efficacy to escitalopram for major depressive disorder in head-to-head trials 6
• Significantly lower sexual dysfunction rates compared to SSRIs (8% vs 18-30% with SSRIs), making it preferable when sexual side effects are problematic 7, 3
• Lower weight gain risk: Bupropion is associated with 0.22 kg less weight gain at 6 months compared to sertraline, and 15% reduced risk of gaining ≥5% body weight 8
• In SSRI non-responders, switching to bupropion produces response rates of 35-60% 9, 10

Ongoing Assessment Timeline

Weeks 2-4

• Continue monitoring for neuropsychiatric adverse effects (highest risk period extends through first 2 months) 3
• Assess early therapeutic response—initial improvements in energy or activation may appear within days to weeks 3
• Evaluate tolerability and consider dose adjustment to 300mg if response is inadequate and 150mg is well-tolerated 2

Weeks 6-8

• Conduct formal efficacy assessment: A full therapeutic trial requires 6-8 weeks at adequate dose 3
• If inadequate response after 6-8 weeks at therapeutic dose, consider alternative strategies (dose adjustment, augmentation, or switching agents) 3
• Do not deem bupropion ineffective before completing this full trial period 3

Month 4 and Beyond

• After remission of a first depressive episode, continue bupropion for at least 4-9 months to reduce relapse risk 11, 3
• For recurrent depression, longer maintenance therapy is advised 11, 3

Common Pitfalls to Avoid

1. Abrupt escitalopram discontinuation: This significantly increases discontinuation syndrome risk, particularly with shorter-acting SSRIs like escitalopram 1

2. Starting bupropion in agitated depression: Bupropion's activating properties may worsen agitation; it is better suited for patients with low energy, apathy, or fatigue 3

3. Premature dose escalation: Rapid titration increases seizure risk—the gradual approach (150mg for at least 4 days before increasing) minimizes this danger 2

4. Evening dosing: Taking bupropion after 3 PM substantially increases insomnia risk 3

5. Inadequate seizure risk assessment: Failing to screen for eating disorders, alcohol withdrawal, or other seizure risk factors before prescribing bupropion 3, 2

6. Insufficient monitoring duration: The highest risk for neuropsychiatric adverse effects extends through the first 2 months, not just the first week 3

Special Populations

• Renal impairment (GFR <90 mL/min): Reduce dose and/or frequency of bupropion 2
• Hepatic impairment (Child-Pugh 5-6): Consider dose/frequency reduction; (Child-Pugh 7-15): Maximum 150mg every other day 2
• Elderly or medically frail: Employ slower titration schedules to improve tolerability 3